KPTI - Karyopharm Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KPTI is currently covered by 5 analysts with an average price target of $12.27. This is a potential upside of $31.72 (662.11%) from yesterday's end of day stock price of $1.61.

Karyopharm Therapeutics's activity chart (see below) currently has 57 price targets and 96 ratings on display. The stock rating distribution of KPTI is 14.29% HOLD and 85.71% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 49.78% with an average time for these price targets to be met of 365.43 days.

Highest price target for KPTI is $28, Lowest price target is $3, average price target is $12.27.

Most recent stock forecast was given by MICHAEL ULZ from BAIRD on 31-Jul-2026. First documented stock forecast 02-Jun-2015.

Currently out of the existing stock ratings of KPTI, 2 are a HOLD (14.29%), 12 are a BUY (85.71%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 03-Nov-2023

$3

$1.39 (86.34%)

$15

1 months 12 days ago
(31-Jul-2026)

3/6 (50%)

$1.08 (56.25%)

1410

Buy Since 09-Oct-2025

$7

$5.39 (334.78%)

$16

1 months 12 days ago
(31-Jul-2026)

1/4 (25%)

$5.08 (264.58%)

10

Buy Since 18-Feb-2026

$3

$1.39 (86.34%)

$13

1 months 12 days ago
(31-Jul-2026)

1/5 (20%)

$1.08 (56.25%)

15

Buy Since 10-Mar-2026

$28

$22.52 (410.95%)

$330

6 months 2 days ago
(10-Mar-2026)

1/2 (50%)

$19.77 (240.22%)

1085

Buy Since 06-Jan-2023

$19

$8.79 (86.09%)

10 months 8 days ago
(04-Nov-2025)

7/17 (41.18%)

$13.35 (236.28%)

312

Show more analysts

Please expand the browser size to see the chart

What is KPTI (Karyopharm Therapeutics) average time for price targets to be met?

On average it took 365 days for the stock forecasts to be reached, with an average price target met ratio of 49.78%.

Which analyst most recently updated their price target on KPTI (Karyopharm Therapeutics)?

Michael Ulz

Which analyst has the most public recommendations on KPTI (Karyopharm Therapeutics)?

Michael Ulz works at MORGAN STANLEY and has 6 price targets and 10 ratings on KPTI

Which analyst is the currently most bullish on KPTI (Karyopharm Therapeutics)?

Maury Raycroft with the highest potential upside of $517

Which analyst is the currently most reserved on KPTI (Karyopharm Therapeutics)?

Jonathan Chang with the lowest potential downside of -$4.21

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?